Bristol-Myers, Celgene Shares Both Lower as Merger Faces Delays
June 24 2019 - 3:30PM
Dow Jones News
By Stephen Nakrosis
Shares of Bristol-Myers Squibb Co. (BMY) and Celgene Corp.
(CELG) are both in the red in Monday's market, following news their
planned merger would be delayed due to antitrust concerns.
At 2:51 p.m. ET, Bristol-Myers Squibb shares had lost 7.4%, to
trade at $45.69. Volume was heavier than usual, with over 29.1
million shares trading, above the 65-day average volume of some
14.6 million. Celgene shares had lost 5.34%, trading at $93.63.
That stock's volume was also higher than usual with over 7.2
million shares trading, above its 65-day average volume of some 6.6
million.
The $74 billion merger faces delays as the companies work to
sell Celgene's anti-inflammatory drug, Otzela, in an effort to
address concerns raised by antitrust regulators.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 24, 2019 15:15 ET (19:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024